Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000547916 | SCV000626183 | uncertain significance | Fanconi anemia | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 106 of the FANCA protein (p.Gly106Ala). This variant is present in population databases (rs764893807, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with FANCA-related conditions. ClinVar contains an entry for this variant (Variation ID: 456110). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000764092 | SCV000895056 | uncertain significance | Fanconi anemia complementation group A | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000764092 | SCV001522899 | uncertain significance | Fanconi anemia complementation group A | 2019-11-05 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Natera, |
RCV000547916 | SCV002090780 | uncertain significance | Fanconi anemia | 2020-02-14 | no assertion criteria provided | clinical testing |